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Statins mediate many of their protective effects by lowering
lipids as well as by modulating inflammation. Here, we
studied their potential immunomodulatory role in renal
inflammation using an autoimmune mouse model of
anti-glomerular basement membrane glomerulonephritis.
Oral treatment with Atorvastatin dramatically reduced
albuminuria and histological changes in the kidneys as
compared to vehicle-treated control animals. There was a
significant decrease in the Th1 and Th17 response in the
regional lymph nodes draining the kidneys. This systemic
effect was accompanied by decreased infiltration of
the kidneys with inflammatory CD4þ T and Th17 cells,
macrophages, and neutrophils in statin-treated mice.
Regulatory T cells were not altered in their number, FoxP3
expression, or suppressive capacity, but their interleukin-10
production was significantly increased by statin treatment.
Hence, Atorvastatin systemically and locally decreased the
Th1 and Th17 response, thereby protecting the mice against
anti-glomerular basement membrane glomerulonephritis.
Whether statins can be used to treat human autoimmune
renal diseases will require more direct studies.
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Statins mediate their effect by inhibiting the rate-limiting step
in the cholesterol synthesis pathway and thus reduce the low-
density lipoprotein cholesterol levels. Statin treatment leads
not only to a reduction of cholesterol, but also to an in vivo
depletion of intermediate metabolites in this biochemical
pathway, such as the isoprenoids farnesyl and geranylgeranyl
pyrophosphate, which both function as adjuncts in post-
translational prenylation of various important cell signaling
proteins involved in inflammation.1 Thus, statins inhibit
cytokine-inducible expression of major histocompatibility
complex class II and costimulatory molecules of antigen-
presenting cells, and prevent antigen presentation to CD4þ T
cells. Furthermore, statins are able to alter the T-cell profile by
blocking the secretion of pro-inflammatory cytokines through
inhibition of STAT-4 and T-bet, which are required for Th1
differentiation. In contrast, statins increase the secretion of the
anti-inflammatory Th2 cytokines through activation of
STAT-6 and GATA-3.2 Recently, the Th1/Th2 paradigm has
been challenged by the identification of a third interleukin
(IL)-17-producing CD4þ effector T-cell subset, named Th17
cells. The development of Th17 cells has been shown to be
blocked by statins.3 Furthermore, statin treatment has also
been shown to modulate regulatory T cells (Tregs).4,5
Statins indeed showed a promising therapeutic potential
for the treatment of experimental allergic encephalomyelitis,
collagen-induced arthritis, asthma, and graft-versus-host
disease.6–10 Treatment with statins even found its way from
bench to bedside, as clinical trials in patients with
rheumatoid arthritis and graft-versus-host disease found
statins to be beneficial.11,12
So far, the use of statin in the field of nephrology has been
disappointing. The ALERT study in patients undergoing
kidney transplantation, as well as the 4D and AURORA study
in patients undergoing hemodialysis, showed no benefit in
cardiovascular end points from statin treatment.13–15 On the
other side, there is an effect of statin treatment on the
inflammatory biomarker C-reactive protein in apparently
healthy persons without hyperlipidemia.16 Furthermore,
experimentally positive effects of statins in animal models
of glomerulonephritis (GN) have been reported. Statins have
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been shown to be beneficial in lupus nephritis,17 nephrotoxic
nephritis,18 diabetic db/db mice,19 and in anti-Thy1 nephritis
in rats.20 Thus, statins seem to modulate the progression of
inflammatory kidney disease, but may come too late to
translate into consistent improvement of cardiovascular
outcome in end-stage renal failure.13,14,21,22
To date, data on the effect of statins in the autologous
phase of anti-glomerular basement membrane (GBM) GN
are lacking. As the T-cell subsets Th1, Th17, and Tregs are
modulated by statin treatment and are key players in the
pathogenesis of experimental anti-GBM GN,23–26 statins
could be of help in the management of GN. Treatment of
human GN is still a challenge and new therapeutic options
are eagerly awaited. Here, we provide evidence that
Atorvastatin locally and systemically decreases the Th1 and
Th17 response and thereby protects against anti-GBM GN.
RESULTS
Atorvastatin treatment attenuates renal damage in
anti-GBM GN
Statin treatment has been shown to limit anti-GBM GN,18
but so far the mechanisms are unknown. Therefore, we
treated mice with 10mg/kg body weight Atorvastatin or
vehicle starting on the day of immunization and induced the
autologous model of anti-GBM GN. As shown in Figure 1a,
mice treated with Atorvastatin developed less albuminuria on
day 7 when compared to controls. This difference reached
significance on day 14. Histological changes in the kidneys
were only mild on day 7 after induction of anti-GBM GN.
After 14 days, hypercellularity and focal deposition of
periodic acid Schiff (PAS)-positive material, massive inter-
stitial infiltration, tubular damage (Figure 1b), and occa-
sional small crescent formations were observed in mice
receiving vehicle after induction of anti-GBM GN. In
contrast, these changes were not seen in mice treated with
Atorvastatin (Figure 1c). Counting PASþ deposits revealed
significantly decreased amounts of PASþ deposits in mice
treated with Atorvastatin as compared to respective controls
14 days after induction of anti-GBM GN (Figure 1d).
Atorvastatin treatment not only decreased the inflammatory
response in the kidneys, but also reduced the inherent
hyperlipidemia in this animal model of anti-GBM GN
(Table 1). There was no difference in plasma cholesterol
and triglyceride levels on day 7 after induction of disease.
However, on day 14, the Atorvastatin-treated mice displayed
a more favorable lipoprotein profile with lower very low-
density lipoprotein and low-density lipoprotein triglyceride
(Figure 2a) and cholesterol levels (Figure 2b) when compared
to vehicle-treated controls. Moreover, the observed protective
Atorvastatin effect was abrogated by the daily intraperitoneal
treatment with 20mg/kg body weight mevalonate (data not
shown). The humoral response, evaluated by the detection of
circulating mouse anti-rabbit antibodies, as well as the
deposition of heterologous and autologous antibodies on the
glomerular membrane, did not differ between the two groups
(Table 2).
Atorvastatin treatment decreases the systemic Th1 and Th17
response
Very recently, it has been shown that Th1 as well as Th17 cells
have an essential role in the pathogenesis of anti-GBM
GN.23,24,26 Atorvastatin has been shown to decrease both
responses.3,9 In our model of anti-GBM GN, we found
Atorvastatin to decrease marker genes of the Th1 response,
such as T-bet, interferon g (IFN-g), and IL-6, in regional
draining lymph nodes 7 days after induction of anti-GBM
GN (Figure 3). In contrast, no effect was observed on the Th2
response, evaluated by the mRNA expression of GATA-3 and
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Figure 1 |Atorvastatin decreases albuminuria and histological
changes in anti-glomerular basement membrane (GBM)
glomerulonephritis (GN). Mice were treated with either
Atorvastatin (white bar) or vehicle (gray bar), and the autologous
phase of anti-GBM GN was induced. (a) On days 7 (n¼ 20 per
group) and 14 (n¼ 11 per group), the albumin/creatinine ratio in
the urine was evaluated. *Po0.05 by Mann– Whitney U-test.
Representative pictures of periodic acid-Schiff (PAS) stainings of
the kidney from (b) vehicle-treated and (c) Atorvastatin-treated
mice are shown. Original magnification  400. (d) On day 14, PAS-
stained kidney sections of Atorvastatin-treated (white bar) and
vehicle-treated (gray bar) mice (n¼ 11 per group) were scored.
*Po0.05 by Student’s t-test.
Kidney International (2010) 77, 428–435 429
P Eller et al.: Statins in glomerulonephritis o r ig ina l a r t i c l e
transforming growth factor-b (TGF-b). Interestingly, IL-10
was found to be decreased in lymph nodes of Atorvastatin-
treated mice, but significance was not reached (Figure 3). The
Th17 response was significantly decreased by Atorvastatin
treatment as shown by a decrease in the IL-17, IL-21, and
RORgt mRNA in lymph nodes 7 days after induction of anti-
GBM GN (Figure 3). The costimulatory protein CD86 tended
to decrease by Atorvastatin treatment (Figure 3). Interest-
ingly, these effects were not seen any longer in the regional
draining lymph nodes 14 days after induction of anti-GBM
GN (data not shown).
Flow cytometry analysis confirmed the significant
downregulation of intracellular IL-17 from 11.1 to 6.5%
on day 7 after induction of anti-GBM GN (Figure 4) and
showed significantly increased CD4þ T cells in lymph
nodes of Atorvastatin-treated mice compared to vehicle-
treated controls. These CD4þ cells expressed significantly
decreased amounts of the T-cell activation marker CD69.
No differences were detected in the CD8þ T-cell
amount in lymph nodes (Table 3). These effects were not
detectable 14 days after induction of anti-GBM GN (data not
shown).
Atorvastatin treatment decreases the inflammatory response
in the kidney
The autologous model of anti-GBM GN has been shown to
be mediated by CD4þ Th1 cells, macrophages, and Th17
cells.23,24,26,27 We found only marginal infiltration of CD4þ
T cells, macrophages, and Th17 cells into kidneys of
Atorvastatin- and vehicle-treated mice 7 days after induction
of disease (data not shown). After 14 days, we detected
significantly decreased numbers of CD4þ T cells and F4/80þ
cells to infiltrate kidneys of Atorvastatin-treated mice
compared to respective controls (Figure 5a and b). It is
noted that no difference in the infiltration of CD8þ T cells in
the kidneys of Atorvastatin- and vehicle-treated mice was
detected 7 and 14 days after induction of anti-GBM GN (data
Table 1 | Biochemical characteristics of mice with
anti-GBM GN
Day 7 Day 14
Vehicle Atorvastatin Vehicle Atorvastatin
Cholesterol (mg/dl) 95±2 100±4 214±15 168±11
P-value 0.34 0.02*
Triglyceride (mg/dl) 89±3 97±5 219±30 144±16
P-value 0.19 0.03*
Creatinine (mg/dl) 0.14±0.01 0.14±0.01 0.20±0.03 0.16±0.01
P-value 0.76 0.27
Abbreviations: GBM, glomerular basement membrane; GN, glomerulonephritis.
Lipid parameters and serum creatinine levels are given as mean±s.e.m. on day 7
(n=9 per group) and 14 (n=11 per group) after induction of disease. P-values were
determined by unpaired Student’s t-test. *Po0.05
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Figure 2 |Atorvastatin attenuates the inherent hyperlipidemia
in anti-glomerular basement membrane (GBM)
glomerulonephritis (GN). Fast protein liquid chromatography
fractionation analysis was performed by applying pooled serum
samples of five mice on Atorvastatin and five controls to two
tandem Superose 6 columns. On day 14, the Atorvastatin-treated
mice (black circles) displayed lower very low-density lipoprotein
(VLDL) and low-density lipoprotein (LDL) triglyceride and
cholesterol levels when compared to vehicle-treated controls
(gray diamonds).
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Figure 3 |Atorvastatin decreases the systemic Th1 and Th17
response in anti-glomerular basement membrane (GBM)
glomerulonephritis (GN). Mice treated with Atorvastatin (white
bar) or vehicle (gray bar) were subjected to anti-GBM GN. On day
7, mRNA was isolated from regional draining lymph nodes. Real-
time PCR for the detection of T-bet, IL-6, IFN-g, GATA-3, TGF-b,
IL-10, IL-17, IL-21, RORgt, and CD86 was performed. Data are given
as fold increase compared to the respective mRNA expression
in lymph nodes of healthy controls. *Po0.05 by Mann– Whitney
U-test.
Table 2 | Deposition of antibodies on the GBM and the mouse anti-rabbit antibody concentrations are not influenced by
Atorvastatin-treatment
Day 7 Day 14
Vehicle Atorvastatin Vehicle Atorvastatin
Deposition of mouse IgG on the GBM (titer) 1:1600 1:1600 1:3200 1:3200
Deposition of rabbit IgG on the GBM (titer) 1:3200 1:3200 1:3200 1:3200
Mouse anti-rabbit IgG concentrations (OD450) 0.21±0.08 0.22±0.11 0.20±0.08 0.24±0.04
Abbreviations: GBM, glomerular basement membrane; GN, glomerulonephritis.
Mice were treated with Atorvastatin or vehicle and were subjected to the autologous phase of anti-GBM GN and were followed for 7 (n=9 per group) and 14 (n=11 per group)
days. The deposition of mouse and rabbit IgG on the GBM was detected by immunofluorescence microscopy. Mouse anti-rabbit IgG concentrations were measured in the
serum by enzyme-linked immunosorbent assay. Data are given as mean±s.d. No differences were detected between the two groups by unpaired Student’s t-test.
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not shown). In addition, we stained kidney sections for
chloroacetate esterase (CAE)-positive cells, detecting mast
cells and neutrophil granulocytes. Significantly decreased
numbers of CAEþ cells were found in kidneys of Atorvas-
tatin-treated mice 14 days after induction of anti-GBM GN
(Figure 5c). These cell populations were detected in the
intraglomerular (Table 4) and interstitial compartments
(Figure 5a–c). In both compartments, the difference in the
infiltration of respective populations reached significance
between the Atorvastatin- and vehicle-treated mice. In line
with the infiltration data, Th1 cytokine expression as shown
by IFN-g and TNF-a was revealed to be significantly
decreased in kidneys of Atorvastatin-treated mice, whereas
no difference in GATA-3 expression was detected (Figure 5d).
Furthermore, kidneys of Atorvastatin-treated mice displayed
significantly decreased IL-17 mRNA expression (Figure 5d).
The Th17 cell marker RORgt tended to be decreased in
kidneys of Atorvastatin-treated mice, but significance was not
reached (Figure 5d).
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Figure 4 | Atorvastatin decreases the amount of intracellular
IL-17 in CD4þ T cells in anti-glomerular basement membrane
(GBM) glomerulonephritis (GN). Mice treated with Atorvastatin
(Atorva) or vehicle were subjected to anti-GBM GN. On day 7,
lymphocytes were isolated from regional draining lymph
nodes, stimulated, and stained for CD4 and intracellular IL-17.
(a) Representative dot blots of lymph nodes of vehicle- and
Atorvastatin-treated mice are shown. (b) Quantification of IL-17
expressing CD4þ T cells for mice treated with Atorvastatin (white
bar) or vehicle (gray bar) (n¼ 5 per group). *Po0.05 by unpaired
Student’s t-test. APC, allophycocyanine; FITC, fluorescein
isothiocyanate.
Table 3 | T-cell infiltration in lymph nodes is influenced by
Atorvastatin treatment
T cells (%) Vehicle Atorvastatin P-valuea
CD4+ 19.27±1.08 23.91±1.36 *
CD69+ 9.78±0.97 7.00±0.81 *
CD8+ 13.36±0.99 14.76±0.99 n.s.
Abbreviation: n.s., not significant.
Seven days after induction of anti-GBM GN (n=9 per group) flow cytometry analysis
for the infiltration of CD4+, CD69+ and CD8+ T cells into lymph nodes was
performed. Data are given as mean±s.d. *Po0.05.
aBy unpaired Student’s t-test.
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Figure 5 |Atorvastatin decreases CD4þ T cell, macrophage,
neutrophil, and Th17 cell infiltration into kidneys. Mice
treated with Atorvastatin (white bar) or vehicle (gray bar) were
subjected to anti-glomerular basement membrane (GBM)
glomerulonephritis (GN). On day 14, kidney sections (n¼ 11 per
group) were evaluated for the interstitial infiltration of (a) CD4þ
T cells, (b) F4/80þ cells, and (c) CAEþ cells. (d) Expression of T-bet,
IFN-g, TNF-a, Gata-3, IL-17, and RORgt in kidneys was performed
(n¼ 11 per group). *Po0.05 by Mann– Whitney U-test.
Table 4 | Intraglomerular infiltration of CD4+, F4/80+, and
CAE+ cells
Vehicle Atorvastatin P-valuea
CD4+ T cells 23.67±3.11 10.33±1.97 *
F4/80+ cells 12.17±2.71 3.67±1.28 *
CAE+ cells 60.83±6.23 23.17±5.58 *
Abbreviations: CAE, chloroacetate esterase; GBM, glomerular basement membrane;
GN, glomerulonephritis.
Fourteen days after induction of anti-GBM GN (n=11 per group) CD4+, F4/80+ and
CAE+ cells were counted intraglomerularly. The number of positive cells in 50
glomeruli is given. *Po0.05.
aBy unpaired Student’s t-test.
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IL-10 production of CD4þCD25þFoxP3þ Tregs is influenced
by Atorvastatin treatment
Atorvastatin has been suggested to increase the number and
potency of CD4þCD25þFoxP3þ Tregs.4,5 At 7 days after
induction of the autologous phase of anti-GBM GN, we did
detect equal Treg numbers and FoxP3 mRNA expression in
lymph nodes (Figure 6a and b). Furthermore, we performed
suppression assays to evaluate the potency of Tregs. The
suppressive capacity of Tregs of Atorvastatin-treated mice was
comparable to Tregs from vehicle-treated animals (Figure 6c).
Interestingly, CD4þCD25þ Tregs from Atorvastatin-treated
mice produced increased amounts of IL-10 compared to
Tregs from vehicle-treated mice (Figure 6d).
DISCUSSION
Statins have manifold immunomodulatory effects that
have gathered much attention for their potential momentum
in the treatment of autoimmune diseases (reviewed by
Greenwood et al.2). In this study, we provide clear evidence
that Atorvastatin attenuates anti-GBM GN by inhibiting the
Th1 and Th17 response without having large effects on Th2
response or Tregs.
For the past 15 years, it has been appreciated that statins
have antiproliferative effects on lymphocytes and other cell
types.28,29 More recent studies have indicated that statins also
have immunomodulatory properties that alter the function of
both T cells and antigen-presenting cells.2 In our model of
anti-GBM GN, we found Atorvastatin to decrease the function
of antigen-presenting cells, as shown by the decrease of the
costimulatory molecule CD86 in the regional draining lymph
nodes of the kidneys 7 days after induction. In most
experimental designs, statins prevented the induction of Th1
cell-mediated autoimmune diseases such as systemic lupus
erythematosus, rheumatoid arthritis, and experimental auto-
immune encephalitis.7,9,17,30 As the autologous phase of anti-
GBM GN is also mediated by Th1 cells, we tested for the
specific effect of Atorvastatin treatment on the course and the
inherent immunoregulation of experimental anti-GBM GN.
We found Atorvastatin to limit the Th1 response by
decreasing the master switch gene of Th1 cells, T-bet. In line,
Th1 marker cytokines, such as IFN-g and IL-6, were
significantly decreased in the regional draining lymph nodes.
Furthermore, in line with Zeiser et al.,10 proliferation of
CD4þCD25 T cells was impaired by Atorvastatin in anti-
GBM GN. The systemic inhibition of the Th1 response on
day 7 was followed by decreased infiltration of CD4þ T cells
into kidneys 14 days after induction of anti-GBM GN. Thus,
our findings nicely complement data by Phoon et al.,31 who
have recently shown that T-bet deficiency attenuates renal
injury in experimental crescentic GN. Statins led to a shift
toward Th2 response in some experimental settings.9,32
However, in our anti-GBM GN, no significant activation of
Th2 cells was seen, neither in the master switch gene GATA-3
nor in the cytokine marker TGF-b.
Very recently, two T-cell subsets, namely Tregs and Th17
cells, carved out their own place in the pathology of
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Figure 6 |Atorvastatin increases IL-10 production of regulatory T cells (Tregs). Mice treated with Atorvastatin (white bar) or vehicle
(gray bar) were subjected to anti-glomerular basement membrane (GBM) glomerulonephritis (GN) (n¼ 9 per group). On day 7 (a) the
percentage of CD4þCD25þFoxP3þ T cells in the draining lymph nodes was evaluated by flow cytometry. (b) The FoxP3 mRNA expression
in the draining lymph nodes was measured. (c) The suppressive capacity of Tregs was evaluated by co-incubating CD4þCD25þ of either
Atorvastatin- or vehicle-treated mice with CD4þCD25 T cells isolated from the spleens and lymph nodes of healthy mice in a ratio of 1:1,
1:2, 1:5, and 1:10 for 7 days. (d) Supernatants of the co-incubation experiments were evaluated for their IL-10 concentration. *Po0.05 by
Mann–Whitney U-test.
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anti-GBM GN.23–25 These two populations seem to
counteract each other. Although Tregs exert their regulatory,
immunosuppressive capacities in the regional draining
lymph nodes, Th17 cells might be the main effector cells in
the target organ not only in anti-GBM GN,23–25 but also in
many other autoimmune diseases.33 In humans, statin
treatment led to an increase of FoxP3 expression in Tregs
and to an increased suppressive capacity of Tregs in vitro and
in vivo.4 The effects of statins on Tregs in mice seem to
depend on the particular inbred strain. In BALB/c mice,
statins enhanced the differentiation of FoxP3þ T cells
through inhibition of geranylgeranylation and induction of
SOCS3 expression.34 In C57BL/6 mice, statins were reported
to have no effect on the number and function of Tregs.4 This
is in accordance with our findings in C57BL/6 mice.
However, we detected an increased IL-10 production by
CD4þCD25þ Tregs. In contrast, we found a trend toward a
decrease in IL-10 mRNA expression in lymph nodes of
Atorvastatin-treated mice. IL-10 is an immunosuppressive
cytokine, but is also expressed by Teffector cells and seems to
be a self-control for Th1 cells (reviewed by Trinchieri 35). The
observed downregulation in whole lymph nodes might
therefore only represent the decreased number of Th1 cells.
In contrast, isolated Tregs of Atorvastatin-treated mice
produce increased IL-10. There exist different subsets of
Tregs, namely naturally occurring CD4þCD25þFoxP3þ
Tregs and adaptive type 1 regulatory cells. The latter arise
in the periphery on encountering antigen in a tolerogenic
environment and produce high levels of IL-10 and mediate
suppression through IL-10.36 As already hypothesized by
Broady and Levings37 concerning the influence of statins on
graft-versus-host disease, it might hold true that Atorvastatin
favors the development of type 1 regulatory cells and might
thereby contribute to the detected immunosuppressive effect
of Atorvastatin in vivo. On the other hand, we were able to
confirm previous data that statin treatment decreased Th17
cells.3,34 We found IL-17 to be significantly decreased in
Atorvastatin-treated mice 7 days after induction of anti-GBM
GN. This finding was associated with a decreased IL-21
mRNA expression, which is a typical cytokine of Th17 cells.38
This was followed by less infiltration of Th17 cells to the
kidneys 14 days after induction of disease. Interestingly, the
Th17 specific marker RORgt was not found to be
significantly decreased by Atorvastatin treatment, which led
us to speculate that Atorvastatin treatment might directly
inhibit IL-17 mRNA transcription.
Thus, the decreased neutrophil and macrophage infiltra-
tion into kidneys of Atorvastatin-treated animals might be
secondary to the decreased Th1 and Th17 response. In
parallel, statins may also have caused lower expression levels
of endothelial cell adhesion molecules, such as ICAM 1, and
its ligand CD11b/CD18 on leukocytes, thereby limiting the
influx of neutrophils and macrophages into the periphery.2,39
Interestingly, we found a time dependency in the effect of
Atorvastatin. In the early phase of disease, we found
Atorvastatin to systemically decrease the inflammatory
response as shown by the evaluation of regional draining
lymph nodes. This was later followed by decreased infiltra-
tion of effector T cells and macrophages to the kidneys,
thereby leading to the attenuation of disease. These data
support the hypothesis that immune regulation in experi-
mental anti-GBM GN takes place in the regional draining
lymph nodes rather than in the kidney.25,40–42
Clinical studies evaluating the effects of statins on
cardiovascular end points in patients undergoing kidney
transplant or hemodialysis have so far been disappoint-
ing.13–15 Nevertheless, our data recommend the use of statins
in autoimmune kidney diseases, where new therapeutic
options are eagerly awaited.
Taken together, Atorvastatin significantly modulated the
immune response by decreasing the Th1 and Th17 response
and thereby attenuated anti-GBM GN. Our study thus
provides a clear rationale to perform clinical trials to evaluate
the therapeutic potential of statins in the treatment of GN.
MATERIALS AND METHODS
Study design
Male C57Bl/6J mice (8- to 12-week old) obtained from Charles
River (Sulzfeld, Germany) were used throughout the studies.
Animals were maintained in a virus/antibody-free central animal
facility of the Innsbruck Medical University. Accelerated anti-GBM
GN was induced as previously described.43 In brief, mice were
preimmunized subcutaneously with 2mg/ml rabbit IgG (Jackson
ImmunoResearch Laboratories, West Grove, PA, USA) dissolved in
incomplete Freund’s adjuvant (Sigma, St Louis, MO, USA) and
nonviable desiccated Mycobacterium tuberculosis H37a (Difco
Laboratories, Detroit, MI, USA). After 3 days, heat-inactivated
rabbit anti-mouse GBM antiserum was injected through the tail
vein. Twenty-four-hour urine samples were collected in metabolic
cages at the indicated time points. All animal experiments were
approved by Austrian veterinary authorities.
In vivo drug treatments
Atorvastatin (LC Laboratories, Woburn, MA, USA) was dissolved in
a stock solution of ethanol and subsequently diluted in 0.5%
methylcellulose (Carl Roth, Karlsruhe, Germany). 100 ml was
administered to mice orally (10mg/kg body weight/day), once
daily, using an infusion canule with a bulb end (Acufirm Ernst Kratz
Nadelfabrik, Dreieich, Germany). As there is a very strong
compensatory increase in 3-hydroxy-3-methylglutaryl coenzyme A
reductase occurring in mice under statin treatment, 10-fold higher
dosing regimes are needed when compared to those in humans.44,45
Mice treated with the vehicle ethanol in 0.5% methylcellulose served
as controls. Mevalonate (Sigma) was dissolved in phosphate-
buffered saline and injected in a concentration of 20mg/kg body
weight intraperitoneally once daily. All treatments were initiated on
the day of immunization.
Creatinine, lipid, and urinary albumin detection
Creatinine was quantified spectrophotometrically using a picric
acid-based method (Sigma). Total cholesterol and triglyceride serum
levels were measured enzymatically (ABX Diagnostics, Montpellier,
France) and urinary albumin (Abcam, Cambridge, MA, USA) was
determined by a double-sandwich enzyme-linked immunosorbent
assay as previously reported.43 For further characterization of
dyslipidemia, the serum samples of five mice on Atorvastatin and
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five controls were combined and subjected to fast protein liquid
chromatography fractionation analysis with two tandem Superose
6 columns (GE Healthcare, Vienna, Austria).46
Assessment of glomerular injury and immune cell infiltration
Formalin-fixed renal tissue was embedded in paraffin, 4-mm
sections, and stained with PAS for histological analysis. In all cases,
a minimum of 50 equatorial glomerular cross sections were
evaluated as previously described.47 The three-layer immunoperox-
idase technique on frozen tissue sections (4 mm) was used for the
detection of macrophages and T cells in the kidney sections.
Macrophages were stained using the rat anti-mouse F4/80 antibody
(Serotec, Oxford, UK). A semiquantitative scoring system was
performed as follows: 0, 0–4 cells stained positive; 1þ , 5–10 cells;
2þ , 10–50 cells; 3þ , 50–200 cells; and 4þ , 4200 cells stained
positive per low-power field. For the detection of CD4þ T cells,
a rat anti-mouse CD4 mAb (clone YTS191.1; Serotec) was used.
A biotin-conjugated goat anti-rat IgG antibody (Jackson
ImmunoResearch Laboratories) was used as a secondary antibody,
followed by incubation with an avidin–biotin complex and
subsequent development with 0.4% 3-amino-9-ethylcarbazole for
6min and counterstaining with Gill’s Hematoxylin No. 3 (Poly-
sciences, Warrington, PA, USA). Quantification of T cells was
performed by counting the number of cells in six adjacent high-
power fields of the renal cortex and medulla. Furthermore, the
number of positive CD4þ , F4/80þ , and CAEþ cells was evaluated
in 50 glomerular cross sections.
Neutrophil infiltration was assessed by the dichloroacetate
esterase reaction on paraffin sections as previously described.48
The number of positive cells was counted in glomerular and cortical
interstitia in 50 high-power fields.
For the detection of heterologous and autologous IgG deposi-
tion, sections were stained by direct immunofluorescence with a
fluorescein isothiocyanate-conjugated goat anti-rabbit IgG or goat
anti-mouse IgG (Jackson ImmunoResearch Laboratories). Semi-
quantitative assessment of the glomerular deposition of IgG was
performed by determining the end point positive titer for detection
of staining using serial dilutions of each antibody.
Detection of circulating IgG
For detection of circulating mouse anti-rabbit IgG, including
respective mouse IgG subclasses, 96-well plates (Greiner, Krems-
muenster, Austria) were coated with 100mg/ml rabbit IgG in
carbonate/bicarbonate buffer (pH 9.5) overnight at 41C, and the
plate was blocked with 1% bovine serum albumin. Plates were
washed with phosphate-buffered saline containing 0.05% Tween-20
and then incubated with serial-doubling dilutions of mouse serum,
starting at 1:3200. After further washing, bound mouse IgG was
detected with horseradish peroxidase-conjugated goat anti-mouse
IgG (Dako, Glostrup, Denmark) at a dilution of 1:2000. Serum of
nonimmunized mice was used as control.
Reverse transcription real-time PCR
Total RNA was isolated using TRIzol (Sigma) according to a standard
protocol. Thereafter, 2mg of total RNA was reverse transcribed using a
Superscript III Transcription Kit (Invitrogen, Carlsbad, CA, USA) and
random primers (Roche, Basel, Switzerland). Real-time PCR was
performed on an ABI Prism 7700 (Applied Biosystems, Foster City, CA,
USA). For linear amplification of FoxP3, SYBR Green Master Mix
(Invitrogen) and the following primers were used: FoxP3: forward
50-TCTTGCCAAGCTGGAAGACT-30, reverse 50-AGCTGATGCATGA
AGTGTGG-30; TNF-a: forward 50-GAACTGGCAGAAGAGGCACT-30,
reverse 50-AGGGTCTGGGCCATAGAACT-30. For quantification of
T-bet, IL-6, IFN-g, GATA-3, TGF-b, IL-10, IL-17, IL-21, RORgt,
and CD86, TaqMan Mastermix (Applied Biosystems) and the gene
expression assays Mm00450960_m1, Mm00446190_m1, Mm00901778_
m1, Mm00484683_m1, Mm03024053_m1, Mm00439616_m1,
Mm00439619_m1, Mm00517640_m1, Mm01261022_m1, and
Mm00444543_m1 (Applied Biosystems) were used. 18S served as
the reference gene.
Flow cytometry analysis
Single-cell suspensions from draining lymph nodes were performed.
Cells were stained with antibodies directed against mouse CD4,
CD25, CD96, CD8 (Immunotools, Friesoythe, Germany), and
FoxP3 (BioLegend, San Diego, CA, USA). Staining of intracellular
IL-17 was performed as recently described.24 In brief, isolated
leukocytes were activated by incubation at 371C, 5% CO2 for 5 h
with PMA (5 ng/ml; Sigma) and ionomycin (1 mg/ml; Sigma) in
Dulbecco’s modified Eagle’s medium (Gibco, Grand Island, NY,
USA) with 10% fetal calf serum. After 30min of incubation,
brefeldin A (10 mg/ml; Sigma) was added. After several washing steps
and staining of CD4, cells were incubated with Cytofix/Cytoperm
(BD Biosciences, Franklin Lakes, NJ, USA) for 20min at 41C to
permeabilize cell membranes. Then, intracellular IL-17 was stained
using a rat anti-mouse IL-17 antibody and a respective isotype
control (BioLegend). Flow cytometry evaluations were performed
on an Epics XL-MCL Flow Cytometry System (Beckman Coulter,
Fullerton, CA, USA) or a BD FACS Calibur System (BD
Biosciences). Data were collected from at least 10,000 events.
Treg suppression assays
At 7 days after induction of anti-GBM, spleens and lymph nodes
from Atorvastatin- and vehicle-treated mice were harvested. Single-
cell suspensions were performed and CD4þCD25þ Tregs were
isolated and separated from CD4þCD25 T cells using magnetic
bead separation (CD4þCD25þ regulatory T-cell kit; Miltenyi
Biotec, Bergisch Gladbach, Germany). CD4þCD25 T cells were
isolated from healthy controls.
To determine the regulatory properties of the Tregs, we performed
cocultures of CD4þCD25 T cells isolated from untreated animals
together with different numbers of Tregs isolated from either
Atorvastatin- or vehicle-treated mice in anti-CD3 (5mg/ml) precoated
wells. As control, the respective T-cell populations were cultured
alone. Proliferation was measured at day 7 by 3H-thymidine
incorporation in a b-scintillator. Supernatants were evaluated for
their IL-10 concentration by using commercially available enzyme-
linked immunosorbent assay kits (Pharmingen, San Diego, CA, USA).
Statistical analysis
Results are presented as means±s.e.m. Normal distributions of data
were assessed by the Kolmogorov–Smirnov test with Lilliefors
correction. Both groups were compared by either nonparametric
Mann–Whitney U-test or unpaired t-test as appropriate, depending
on the distribution of the tested variable. A two-tailed Po0.05 was
considered statistically significant. All statistical analyses were
performed with SPSS 12.0.1 for Windows (SPSS, Chicago, IL, USA).
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